PMID- 31081045
OWN - NLM
STAT- MEDLINE
DCOM- 20190830
LR  - 20211204
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 54
IP  - 6
DP  - 2019 Jun
TI  - Harmine induces anticancer activity in breast cancer cells via targeting TAZ.
PG  - 1995-2004
LID - 10.3892/ijo.2019.4777 [doi]
AB  - Harmine (HM) is a beta‑carboline alkaloid found in multiple medicinal plants. It has 
      been used in folk medicine for anticancer therapy; however, the molecular 
      mechanism of HM on human breast cancer remains unclear. Transcriptional 
      co‑activator with PDZ‑binding motif (TAZ), also known as WW domain‑containing 
      transcription regulator 1, serves an important role in the carcinogenesis and 
      progression of breast cancer. The aim of the present study was to elucidate the 
      potential anticancer activity and mechanism of HM in breast cancer, in vitro and 
      in vivo. Cell proliferation was measured using a CCK‑8 assay, apoptotic activity 
      was detected by flow cytometry and DAPI staining, and cell migration was examined 
      using a wound healing assay. The expression of proteins, including extracellular 
      signal‑regulate kinase (Erk), phosphorylated (p‑) Erk, protein kinase B (Akt), 
      p‑Akt, B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑associated X protein (Bax), were 
      determined by western blotting. The mRNA expression of TAZ was detected using 
      reverse transcription‑quantitative polymerase chain reaction analysis. The 
      expression of proteins in mouse tumor tissues were examined by 
      immunohistochemistry. HM significantly suppressed cellular proliferation and 
      migration, promoted apoptosis in vitro and inhibited tumor growth in vivo. In 
      addition, HM significantly decreased the expression of TAZ, p‑Erk, p‑Akt and 
      Bcl‑2, but increased that of Bax. The overexpression of TAZ in breast cancer 
      cells inhibited the antitumor effect of HM. In conclusion, HM was found to induce 
      apoptosis and prevent the proliferation and migration of human breast cancer cell 
      lines, possibly via the downregulation of TAZ.
FAU - Ding, Yu
AU  - Ding Y
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - He, Jinrong
AU  - He J
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - Huang, Juan
AU  - Huang J
AD  - Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China.
FAU - Yu, Tong
AU  - Yu T
AD  - Department of Traditional Chinese Medicine, Humanwell Healthcare (Group) Co., 
      Ltd., Wuhan, Hubei 430075, P.R. China.
FAU - Shi, Xiaoyan
AU  - Shi X
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - Zhang, Tianzhu
AU  - Zhang T
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - Yan, Ge
AU  - Yan G
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - Chen, Shanshan
AU  - Chen S
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
FAU - Peng, Caixia
AU  - Peng C
AD  - Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of 
      Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, Hubei 430014, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190409
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 0 (Transcriptional Coactivator with PDZ-Binding Motif Proteins)
RN  - 0 (WWTR1 protein, human)
RN  - 4FHH5G48T7 (Harmine)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/pharmacology
MH  - Breast Neoplasms/*drug therapy/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Harmine/*administration & dosage/pharmacology
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - MCF-7 Cells
MH  - Signal Transduction/drug effects
MH  - Trans-Activators
MH  - Transcription Factors
MH  - Transcriptional Coactivator with PDZ-Binding Motif Proteins
MH  - Xenograft Model Antitumor Assays
PMC - PMC6521938
EDAT- 2019/05/14 06:00
MHDA- 2019/08/31 06:00
PMCR- 2019/04/09
CRDT- 2019/05/14 06:00
PHST- 2018/10/26 00:00 [received]
PHST- 2019/03/27 00:00 [accepted]
PHST- 2019/05/14 06:00 [entrez]
PHST- 2019/05/14 06:00 [pubmed]
PHST- 2019/08/31 06:00 [medline]
PHST- 2019/04/09 00:00 [pmc-release]
AID - ijo-54-06-1995 [pii]
AID - 10.3892/ijo.2019.4777 [doi]
PST - ppublish
SO  - Int J Oncol. 2019 Jun;54(6):1995-2004. doi: 10.3892/ijo.2019.4777. Epub 2019 Apr 
      9.